← Browse by Condition

Medical Condition

acute myeloid leukemia

Total Trials

38

Recruiting Now

38

Trial Phases

Phase 2, Phase 3, Phase 1

NCT04195633 Phase 2

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Fred Hutchinson Cancer Center

NCT04168502 Phase 3

Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Gruppo Italiano Malattie EMato...

A Telehealth Advance Care Planning Intervention

University of Rochester

NCT06713837 Phase 3

IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

Czechia, Germany, It...

Istituto Romagnolo per lo Stud...

NCT05031897 Phase 2

Two Step Haplo With Radiation Conditioning

Thomas Jefferson University

NCT06440135 Phase 1

Ziftomenib Maintenance Post Allo-HCT

Massachusetts General Hospital

NCT03471260 Phase 1, Phase 2

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

M.D. Anderson Cancer Center

NCT06195891 Phase 1

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

City of Hope Medical Center

Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.

Huai'an First People's Hospita...

NCT06575296 Phase 1

Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant

City of Hope Medical Center

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Alliance for Clinical Trials i...

NCT05184842 Phase 2

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

Montefiore Medical Center

NCT07356154 Phase 1, Phase 2

A Study of Revumenib and Mezigdomide in People With Leukemia

Memorial Sloan Kettering Cance...

NCT05401097 Phase 2

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

NCT06928662 Phase 1, Phase 2

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Fred Hutchinson Cancer Center

NCT06651866 Phase 1

Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients

The First Affiliated Hospital ...

NCT05101551 Phase 1

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

Norman J. Lacayo

NCT05995028 Phase 1

Universal 4SCAR7U Targeting CD7-positive Malignancies

Shenzhen Geno-Immune Medical I...

NCT04662294 EARLY_Phase 1

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

Zhejiang University

NCT04293562 Phase 3

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

United States, Austr...

Children's Oncology Group

Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Institute of Hematology & Bloo...

NCT06737523 Phase 1

Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML

The First Affiliated Hospital ...

NCT06514261 Phase 1

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

National Cancer Institute (NCI...

NCT06297941 Phase 1

Study of REM-422 in Patients With AML or Higher Risk MDS

United States, Franc...

Remix Therapeutics

NCT06880354 Phase 1

A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Institute of Hematology & Bloo...

NCT06221683 Phase 2

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

Children's Hospital of Soochow...

NCT06824168 Phase 2

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

United States, Austr...

NCT03589729 Phase 2

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

NCT06389292 Phase 3

A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

Ascentage Pharma Group Inc.

Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement

Shanghai General Hospital, Sha...

NCT06594445 Phase 1

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

Masonic Cancer Center, Univers...

NCT02115295 Phase 2

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

M.D. Anderson Cancer Center

The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia

Ruijin Hospital

NCT05834244 Phase 1

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

M.D. Anderson Cancer Center

NCT04953897 Phase 1

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

United States, Armen...

Taiho Oncology, Inc.

NCT04811560 Phase 1, Phase 2

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

United States, Austr...

Janssen Research & Development...

NCT07321626 Phase 1

Romiplostim N01 for Platelet Recovery After Haploidentical HSCT

First Affiliated Hospital of Z...

NCT03113643 Phase 1

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Dana-Farber Cancer Institute